As the dog days of summer get doggier, and we wait for the SPA to be received, much, much more Moffitt data to arrive, a dermatology and/or mini-oncology deal(s) to materialize, and other events to occur, it might be constructive and cooling to think about Pfizer...
If the addition of Dr. Craig Eagle to Provectus' corporate advisory board is the tip of the iceberg, what's below the waterline?
 |
| Below-the-waterline items not in chronological order. |
No comments:
Post a Comment